abstract |
The present disclosure relates to a shielded biologic with a masking domain, e.g., based on Insulin-like Growth Factor 2 (IGF2), fused to the Fab domain of an antibody via protease-cleavable linker to mask the antigen binding capability of the antibody, and to the use of said shielded biologic for effective and site-specific disease treatment while reducing systematic toxicity. |